These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30146956)

  • 1. Designing a Delinked Incentive for Critical Antibiotics: Lessons from Norway.
    Årdal C; Johnsen J; Johansen K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):43-49. PubMed ID: 30146956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commentary: innovation policy for a new era.
    Kapczynski A
    J Law Med Ethics; 2009; 37(2):264-8. PubMed ID: 19493071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulating Research and Development of New Antibiotics While Ensuring Sustainable Use and Access: Further Insights from the DRIVE-AB Project and Others.
    Bettiol E; Hackett J; Harbarth S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):5-8. PubMed ID: 30146955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
    Outterson K; McDonnell A
    Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-card patent extensions as a means to incentivize research and development of antibiotics.
    Sonderholm J
    J Law Med Ethics; 2009; 37(2):240-6. PubMed ID: 19493069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How can we improve access to new (and old) antibiotics in Australia?
    Cheng AC; Nation RL
    Med J Aust; 2013 Jul; 199(2):81-2. PubMed ID: 23879485
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of resistant pathogens and antibiotic innovation.
    McKellar MR; Chernew ME; Fendrick AM
    Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Grant Framework as a Push Incentive to Stimulate Research and Development of New Antibiotics.
    Savic M; Årdal C
    J Law Med Ethics; 2018 Jun; 46(1_suppl):9-24. PubMed ID: 30146963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of funding could undermine UK antibiotic resistance strategy, say experts.
    O'Dowd A
    BMJ; 2013 Dec; 347():f7618. PubMed ID: 24355390
    [No Abstract]   [Full Text] [Related]  

  • 14. Countries mull over incentives for developing antibiotics.
    Anderson T
    Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
    [No Abstract]   [Full Text] [Related]  

  • 15. A three-step plan for antibiotics.
    Nature; 2014 May; 509(7502):533. PubMed ID: 24877183
    [No Abstract]   [Full Text] [Related]  

  • 16. Ensuring universal access to old antibiotics: a critical but neglected priority.
    Pulcini C; Beovic B; Béraud G; Carlet J; Cars O; Howard P; Levy-Hara G; Li G; Nathwani D; Roblot F; Sharland M
    Clin Microbiol Infect; 2017 Sep; 23(9):590-592. PubMed ID: 28522030
    [No Abstract]   [Full Text] [Related]  

  • 17. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 18. Universal Access to Effective Antibiotics is Essential for Tackling Antibiotic Resistance.
    Daulaire N; Bang A; Tomson G; Kalyango JN; Cars O
    J Law Med Ethics; 2015; 43 Suppl 3():17-21. PubMed ID: 26243238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics.
    Lum K; Bhatti T; Holland S; Guthrie M; Sassman S
    J Law Med Ethics; 2018 Jun; 46(1_suppl):66-74. PubMed ID: 30146960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.